Charles T. Quinn, MD, MS
- Medical Director, Pediatric Sickle Cell Program
- Director, Erythrocyte Diagnostic Laboratory
- Professor, UC Department of Pediatrics
- charles.quinn@cchmc.org
- Board Certified
About
Biography
I conduct patient-oriented and translational research in sickle cell disease and thalassemia. I am the medical director of the Pediatric Sickle Cell Disease Program and the medical director of the Erythrocyte Diagnostic Laboratory at Cincinnati Children’s Hospital. I am also the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.
MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.
MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.
Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.
Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.
Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.
Interests
Sickle cell disease; thalassemia; hemoglobinopathies; genetics of hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; hereditary spherocytosis (HS); hereditary xerocytosis (HX); immune thrombocytopenia (ITP).
Interests
Identifying the causes of the cardiomyopathy and nephropathy of sickle cell disease and identifying new treatments for these complications; direct measurement of red blood cell turnover (rate of hemolysis); MRI methods for the quantitation of tissue iron; new agents for immune thrombocytopenia (ITP).
Research Areas
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Diastolic dysfunction is associated with exercise impairment in patients with sickle cell anemia. Pediatric Blood and Cancer. 2018; 65:e27113.
Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia. Blood. 2017; 130:205-213.
Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia. American Journal of Hematology. 2016; 91:1195-1201.
Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology. Proceedings of the National Academy of Sciences of USA. 2016; 113:E5182-E5191.
Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease. JACC-Cardiovascular Imaging. 2016; 9:243-252.
The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?. Pediatric Blood and Cancer. 2025; 72:e31475.
Underutilization of Disease-Modifying Therapies in Sickle Cell Disease: A Real-World Analysis from the ASH Research Collaborative Data Hub. Blood. 2024; 144:2312.
Hydroxyurea Pharmacokinetics in Children with Sickle Cell Anemia: Comparison of Global Cohorts. Blood. 2024; 144:542.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey